Perspective of trastuzumab treatment.

被引：8

作者：

Iwata H. ^{[1
]}

机构：

[1] Department of Breast Oncology, Aichi Cancer Center Hospital

来源：

Breast Cancer | 2007年 / 14卷 / 2期

关键词：

Trastuzumab; Metastatic breast cancer; (neo) Adjuvant treatment; Cardiac toxicity;

D O I：

10.2325/jbcs.955

中图分类号：

学科分类号：

摘要：

Trastuzumab (Herceptin) has many benefits for metastatic breast cancer patients with HER2 overexpression/amplification. Trastuzumab alone or trastuzumab in combination with chemotherapy regimens are standard treatment worldwide as first line therapy for metastatic breast cancer patients with HER2 overexpression/amplification. Furthermore, an international collaboration for adjuvant trastuzumab trials showed last year that trastuzumab treatment improves disease-free and overall survival after or in combination with adjuvant chemotherapy. However, there are many uncertain issues concerning trastuzumab adjuvant and metastatic treatment, such as treatment beyond disease progression (PD), combination with hormone therapy, duration of adjuvant treatment, and cardiac safety of long term treatment.

引用

页码：150 / 155

页数：5

共 247 条

[1]

Yarden Y(2001)(Untangling the ErbB signaling network) Nat rev Mol Cell Bio 2 127-137

[2]

Sliwkowski M(1989)Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707-712

[3]

Slamon DJ(2002)(Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer) J Clin Oncol 20 719-726

[4]

Godolphin W(2005)(Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab monotherapy administered on a 3-weekly schedule) J Clin Oncol 23 2162-2171

[5]

Jones LA(2005)(Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer) N Engl J Med 353 1659-1672

[6]

Holt JA(2005)(Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer) N Engl J Med 353 1673-1684

[7]

Wong SG(2001)(Concurrent administration of anti-HER2 monoclonal antibody and firstline chemotherapy for HER2overexpressing metastatic breast cancer. A phase III, multinational, randomized controlled trial) N Engl J Med 344 783-792

[8]

Keith DE(1998)(Treatment of Breast Cancer) N Engl J Med 339 974-984

[9]

Levin WJ(2005)Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor 2-positive metastatic breast cancer administered as first-line treatment: Results of a randomized phase II trial by the M77001 study group J Clin Oncol 23 4265-4274

[10]

Stuart SG(2003)Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markerd as predictive factors, and cardiac surveillance algorithm J Clin Oncol 21 2889-2895

← 1 2 3 4 5 6 7 8 9 10 →